drug · antibody
YUSIMRY
Marketedupdated 6mo agoby $COGT Cogent Biosciences, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval182 co-mentions · 86 sources
- drugHUMIRA172 co-mentions · 86 sources
- drugadalimumab152 co-mentions · 86 sources
- drugAMJEVITA81 co-mentions · 81 sources
- drugABRILADA81 co-mentions · 81 sources
- company$ABBVAbbVie Inc.61 co-mentions · 61 sources
- drugCYLTEZO24 co-mentions · 12 sources
- drugIDACIO16 co-mentions · 8 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 20 investigational indications.
targets
Tumor necrosis factor
all catalysts(5)
approval · 5
Dec 17, 2021
approval
$COGT31.64+6.98%
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→
Feb 27, 2023
approval
$COGT31.64+6.98%
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→
Mar 31, 2023
approval
$COGT31.64+6.98%
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→
Sep 13, 2023
approval
$COGT31.64+6.98%
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→
Nov 10, 2025
approval
$COGT31.64+6.98%
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→
News(10)
- Deaths, failed trials and other recent setbacks in the autoimmune spaceNovartis, Bristol Myers Squibb, argenx and more have recently been hit with challenges as they attempt to advance assets targeting autoimmune diseases, with some programs being axed entirely while…biospace · 1d ago
- AbbVie pens $1.4B deal for deprioritized IBD drug from NxeraAbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase 1 inflammatory bowel disease candidate.fiercebiotech · 13d ago
- AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on dealsStrong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.biospace · 17d ago
- 5 new drug launches that defied industry expectationsA clearly superior clinical profile, reasonable pricing and easy access has helped a handful of recently approved therapies achieve impressive launches.biospace · 20d ago
- AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectationsAbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late-stage trial, but the results have disappointed some analysts, raising q…biospace · 25d ago
- Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye diseaseBrepocitinib is on a roll. After winning approval for an autoimmune skin disease, Roivant Sciences subsidiary Priovant’s drug hit all primary and secondary endpoints in a pair of Phase 3 non-infect…biospace · 26d ago
- Celltrion picks up another Kaigene autoimmune antibody for up to $580.5MCelltrion has licensed a preclinical antibody targeting autoimmune conditions from Maryland-based biotech Kaigene in a deal worth up to $580.5 million, marking another step in the South Korean drug…fiercebiotech · 26d ago
- Roivant, continuing ascent, claims another victory for rare disease drugShortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also be a “best-in-disease” medicine for an inflammatory eye condition, one an…biopharma_dive · 26d ago
- STAT+: Roivant says closely watched immune drug succeeded in new eye diseaseAn immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease non-infectious uveitis.stat · 27d ago
- As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune visionAbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster ca…biospace · 28d ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that